{"nctId":"NCT03088137","briefTitle":"Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment","startDateStruct":{"date":"2017-02-08","type":"ACTUAL"},"conditions":["Infertility, Female"],"count":118,"armGroups":[{"label":"Primapur (Follitropin alfa)","type":"EXPERIMENTAL","interventionNames":["Drug: Follitropin alfa (Primapur)"]},{"label":"Gonal-f (Follitropin alfa)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Follitropin alfa (Gonal-f)"]}],"interventions":[{"name":"Follitropin alfa (Gonal-f)","otherNames":[]},{"name":"Follitropin alfa (Primapur)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infertility due to tubal factor and/or male factor\n* Age between 20 and 35 years with regular menstrual cycles of 21-35 days\n* First or second cycle in the present series of ART\n* BMI (body mass index) ≥ 18 ≤ 30 kg/m2\n* Basal FSH (follicle stimulating hormone) \\< 10 IU/L (cycle day 2-5)\n* E2 (estradiol) levels \\< 50pg/mL (cycle day 2)\n* AMH (anti-mullerian hormone) ≥ 1.0 ng/ml\n* Antral follicle ≥ 4 to ≤ 15 follicles (both ovaries)\n* Presence of both ovaries and normal uterine cavity\n* Informed consent\n\nExclusion Criteria:\n\n* Presence of pregnancy\n* Hypersensitivity to follitropin alfa\n* Ovarian cysts\n* History of ≥2 succeeding ART (assisted reproductive technology) cycles IVF (in vitro fertilization) and/or ICSI (Intracytoplasmic sperm injection) before the study cycle\n* Previous history of severe ovarian hyperstimulation syndrome\n* Presence of polycystic ovaries (PCO)\n* Presence of endometriosis and hydrosalpinx\n* Presence of uterine disorders\n* History of poor (\\< 4 oocytes) or hyper (\\> 25 oocytes) responses to FSH treatment at dose 150 IU and GnRH-antagonist (gonadotropin-releasing hormone) protocol\n* Premature ovarian failure\n* Ectopic pregnancy (3 month before the study cycle)\n* Presence of clinically significant systemic disease\n* Presence of chronic cardiovascular, hepatic, renal or pulmonary disease\n* Presence of endocrine disorder\n* Neoplasia\n* Male infertility without mobile spermatozoa in the ejaculate, that need MESA (Microsurgical epididymal sperm aspiration)/TESE (testicular sperm extraction)/TESA (testicular sperm aspiration)\n* Smoking \\> 10 cigarettes/day\n* Narcomania, alcoholism\n* Planned PGS (preimplantation genetic screeneing) /PGD (preimplantation genetic diagnosis)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Oocytes (Intention-to-Treat, ITT)","description":"The total number of retrieved oocytes at the day of ovum pick-up. No more than 37 hours from the introduction of the trigger of ovulation (hCG or GnRH-agonist). The equivalence in the number of retrieved oocytes was tested using a predetermined equivalence margin of +/- 3.4 oocytes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.16","spread":"7.28"},{"groupId":"OG001","value":"11.62","spread":"6.29"}]}]}]},{"type":"SECONDARY","title":"Number of Follicles With Size ≥ 16 mm","description":"The number of follicles 16 mm or over in diameter at the day of hCG (or GnRH-agonist) administration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.09","spread":"6.159"},{"groupId":"OG001","value":"11.38","spread":"4.965"}]}]}]},{"type":"SECONDARY","title":"Mature Oocytes","description":"The number of mature oocytes (MII stage of development)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.64","spread":"6.270"},{"groupId":"OG001","value":"9.86","spread":"5.546"}]}]}]},{"type":"SECONDARY","title":"Fertilised Oocytes","description":"The number of fertilised oocytes with the presence of two pronuclei: 2PN","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.127","spread":"6.608"},{"groupId":"OG001","value":"8.764","spread":"5.850"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Embryo Transfer","description":"The number of patients (and percentage) with embryo transfers on days 3 and 5 after ovum pick-up","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Dose of Follitropin Alfa","description":"The total dose of the follitropin alfa administrated during the ovarian hyperstimulation protocol (measured in International Units - IU)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1532.7","spread":"267.2"},{"groupId":"OG001","value":"1517.9","spread":"255.2"}]}]}]},{"type":"SECONDARY","title":"Number of Days of Follitropin Alfa Treatment","description":"The duration of ovarian hyperstimulation protocol (at the day of trigger of ovulation)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.745","spread":"1.075"},{"groupId":"OG001","value":"9.727","spread":"1.027"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Follitropin Alfa Dose Correction","description":"The number of dose adjustments during the ovarian hyperstimulation protocol (increment 25-50 IU)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Cycle Cancellation","description":"The number of the ovarian hyperstimulation protocol cancellation (at the day of trigger of ovulation)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of No-responders","description":"The number of patients with no response to follitropin alfa treatment (absence of growing follicles, no any oocytes obtained at the day of ovum pick-up)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Serum hCG More Than 25 IU/l","description":"Biochemical pregnancy test: serum hCG more than 25 IU/l (days 12-17 after embryo transfer)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null},{"groupId":"OG001","value":"36.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With the Evidence for Clinical Pregnancy","description":"Confirmation of clinical pregnancy: ultrasound detection of intrauterine gestational sac and heart activity","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"32.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":55},"commonTop":["Ovarian hyperstimulation syndrome","Lower abdominal pain","Lower abdominal pain","Abnormal vaginal bleeding","Spontaneous miscarriage"]}}}